Jan C. Brase

6.8k total citations
53 papers, 3.0k citations indexed

About

Jan C. Brase is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Jan C. Brase has authored 53 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Cancer Research, 28 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in Jan C. Brase's work include Breast Cancer Treatment Studies (15 papers), Melanoma and MAPK Pathways (10 papers) and Cancer Genomics and Diagnostics (10 papers). Jan C. Brase is often cited by papers focused on Breast Cancer Treatment Studies (15 papers), Melanoma and MAPK Pathways (10 papers) and Cancer Genomics and Diagnostics (10 papers). Jan C. Brase collaborates with scholars based in Germany, Switzerland and United States. Jan C. Brase's co-authors include Holger Sültmann, Ruprecht Kuner, Daniela Wuttig, Maria Fälth, Tim Beißbarth, Marc Johannes, Thorsten Schlomm, Thomas Steuber, Alexander Haese and Mathias Gehrmann and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Bioinformatics.

In The Last Decade

Jan C. Brase

51 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan C. Brase Germany	25	1.9k	1.9k	923	642	216	53	3.0k
Robert J. Lonigro United States	23	1.5k 0.8×	2.5k 1.3×	742 0.8×	1.6k 2.5×	258 1.2×	37	4.0k
Marcin Cieślik United States	23	1.9k 1.0×	3.2k 1.7×	713 0.8×	1.2k 1.8×	180 0.8×	51	4.2k
Hege G. Russnes Norway	23	1.5k 0.8×	1.6k 0.9×	1.1k 1.2×	397 0.6×	405 1.9×	55	3.0k
Oleg Schmidt‐Kittler United States	18	1.2k 0.6×	2.1k 1.1×	1.5k 1.6×	525 0.8×	322 1.5×	24	3.5k
Charles Massie United Kingdom	24	2.1k 1.1×	2.2k 1.2×	1.1k 1.1×	1.3k 2.1×	419 1.9×	42	4.0k
Rebecca Leary United States	11	2.6k 1.4×	2.0k 1.1×	1.7k 1.9×	716 1.1×	367 1.7×	18	4.0k
Hartmut Juhl United States	26	2.0k 1.0×	2.1k 1.1×	1.2k 1.3×	623 1.0×	169 0.8×	65	3.8k
Haili Qian China	31	790 0.4×	1.6k 0.9×	1.0k 1.1×	424 0.7×	136 0.6×	114	2.7k
Kristine Kleivi Sahlberg Norway	26	1.5k 0.8×	1.8k 1.0×	700 0.8×	237 0.4×	173 0.8×	60	2.7k
Patricia Galván Spain	20	997 0.5×	947 0.5×	1.4k 1.5×	671 1.0×	180 0.8×	69	2.4k

Countries citing papers authored by Jan C. Brase

Since Specialization

Citations

This map shows the geographic impact of Jan C. Brase's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan C. Brase with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan C. Brase more than expected).

Fields of papers citing papers by Jan C. Brase

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan C. Brase. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan C. Brase. The network helps show where Jan C. Brase may publish in the future.

Co-authorship network of co-authors of Jan C. Brase

This figure shows the co-authorship network connecting the top 25 collaborators of Jan C. Brase. A scholar is included among the top collaborators of Jan C. Brase based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan C. Brase. Jan C. Brase is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Le, Xiuning, Xiaorong Dong, Herbert H. Loong, et al.. (2025). LBA75 Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study. Annals of Oncology. 36. S1617–S1617.

Solomon, Benjamin, Daniel S.W. Tan, Gilberto de Castro, et al.. (2025). The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer Research Communications. 5(4). 632–646. 1 indexed citations

Goto, Keisuke, et al.. (2024). EP.12H.08 SOHO-02: Phase III Trial of BAY 2927088 In Patients with Locally Advanced or Metastatic NSCLC with HER2-Activating Mutations. Journal of Thoracic Oncology. 19(10). S660–S660. 1 indexed citations

Brase, Jan C., et al.. (2024). 1395TiP A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02). Annals of Oncology. 35. S873–S874. 2 indexed citations

Tawbi, Hussein A., Caroline Robert, Jan C. Brase, et al.. (2022). Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). Journal for ImmunoTherapy of Cancer. 10(6). e004226–e004226. 19 indexed citations

Prat, Aleix, Yi‐Hsuan Tsai, Tomás Pascual, et al.. (2020). A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer. Clinical Cancer Research. 26(23). 6141–6148. 5 indexed citations

Nathan, Paul, Reinhard Dummer, Georgina V. Long, et al.. (2020). LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. Annals of Oncology. 31. S1172–S1172. 48 indexed citations

Long, Georgina V., Axel Hauschild, Mario Santinami, et al.. (2018). Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma. Annals of Oncology. 29. viii734–viii735. 13 indexed citations

Martín, Miguel, Jan C. Brase, Lourdes Calvo, et al.. (2014). Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Research. 16(2). R38–R38. 107 indexed citations

10.

Dubsky, Peter, Jan C. Brase, R. Jakesz, et al.. (2013). The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients. British Journal of Cancer. 109(12). 2959–2964. 235 indexed citations

11.

Jarius, Sven, Pedro J. Martínez‐García, Jan C. Brase, et al.. (2013). Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. Journal of Neuroinflammation. 10(1). 7–7. 33 indexed citations

12.

Kuner, Ruprecht, Maria Fälth, Jan C. Brase, et al.. (2012). The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. Journal of Molecular Medicine. 91(2). 237–248. 119 indexed citations

13.

Dubsky, Peter, Martin Filipits, R. Jakesz, et al.. (2012). EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Annals of Oncology. 24(3). 640–647. 129 indexed citations

14.

Müller, Berit, Jan C. Brase, Karsten E. Weber, et al.. (2012). Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections. Journal of Clinical Pathology. 65(7). 660–662. 25 indexed citations

15.

Kuner, Ruprecht, Jan C. Brase, Holger Sültmann, & Daniela Wuttig. (2012). microRNA biomarkers in body fluids of prostate cancer patients. Methods. 59(1). 132–137. 45 indexed citations

16.

Darb‐Esfahani, Silvia, Ralf Kronenwett, Gϋnter von Minckwitz, et al.. (2012). Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer. British Journal of Cancer. 107(11). 1892–1900. 16 indexed citations

17.

Kronenwett, Ralf, Kerstin Bohmann, Judith Prinzler, et al.. (2012). Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer. 12(1). 456–456. 50 indexed citations

18.

Brase, Jan C., Marcus Schmidt, Thomas Fischbach, et al.. (2010). ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction. Clinical Cancer Research. 16(8). 2391–2401. 108 indexed citations

19.

Johannes, Marc, Jan C. Brase, Holger Fröhlich, et al.. (2010). Integration of pathway knowledge into a reweighted recursive feature elimination approach for risk stratification of cancer patients. Bioinformatics. 26(17). 2136–2144. 75 indexed citations

20.

Brase, Jan C., Heiko Mannsperger, Holger Fröhlich, et al.. (2010). Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification. Proteome Science. 8(1). 36–36. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact